1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Market characteristics analysis
4 Market Sizing
- 4.1 Market definition
- Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ million)
- Data Table on Global - Market size and forecast 2024-2029 ($ million)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5.1 Global Neuromuscular Disease Therapeutics Market 2019 - 2023
- Historic Market Size - Data Table on Global Neuromuscular Disease Therapeutics Market 2019 - 2023 ($ million)
- 5.2 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ million)
- 5.3 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ million)
- 5.4 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.5 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Neuromuscular Disease Therapeutics Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by End-user
- 8.1 Market segments
- Chart on End-user - Market share (2024-2029) (%)
- Data Table on End-user - Market share (2024-2029) (%)
- 8.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 8.3 Hospitals - Market size and forecast (2024-2029)
- Chart on Hospitals - Market size and forecast (2024-2029) ($ million)
- Data Table on Hospitals - Market size and forecast (2024-2029) ($ million)
- Chart on Hospitals - Year-over-year growth (2024-2029) (%)
- Data Table on Hospitals - Year-over-year growth (2024-2029) (%)
- 8.4 Clinics - Market size and forecast (2024-2029)
- Chart on Clinics - Market size and forecast (2024-2029) ($ million)
- Data Table on Clinics - Market size and forecast (2024-2029) ($ million)
- Chart on Clinics - Year-over-year growth (2024-2029) (%)
- Data Table on Clinics - Year-over-year growth (2024-2029) (%)
- 8.5 Others - Market size and forecast (2024-2029)
- Chart on Others - Market size and forecast (2024-2029) ($ million)
- Data Table on Others - Market size and forecast (2024-2029) ($ million)
- Chart on Others - Year-over-year growth (2024-2029) (%)
- Data Table on Others - Year-over-year growth (2024-2029) (%)
- 8.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
- Data Table on Market opportunity by End-user ($ million)
9 Market Segmentation by Type
- 9.1 Market segments
- Chart on Type - Market share (2024-2029) (%)
- Data Table on Type - Market share (2024-2029) (%)
- 9.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 9.3 Biologics - Market size and forecast (2024-2029)
- Chart on Biologics - Market size and forecast (2024-2029) ($ million)
- Data Table on Biologics - Market size and forecast (2024-2029) ($ million)
- Chart on Biologics - Year-over-year growth (2024-2029) (%)
- Data Table on Biologics - Year-over-year growth (2024-2029) (%)
- 9.4 Small molecules - Market size and forecast (2024-2029)
- Chart on Small molecules - Market size and forecast (2024-2029) ($ million)
- Data Table on Small molecules - Market size and forecast (2024-2029) ($ million)
- Chart on Small molecules - Year-over-year growth (2024-2029) (%)
- Data Table on Small molecules - Year-over-year growth (2024-2029) (%)
- 9.5 Market opportunity by Type
- Market opportunity by Type ($ million)
- Data Table on Market opportunity by Type ($ million)
10 Market Segmentation by Disease Type
- 10.1 Market segments
- Chart on Disease Type - Market share (2024-2029) (%)
- Data Table on Disease Type - Market share (2024-2029) (%)
- Market opportunity by Disease Type ($ million)
- Data Table on Market opportunity by Disease Type ($ million)
- 10.2 Comparison by Disease Type
- Chart on Comparison by Disease Type
- Data Table on Comparison by Disease Type
- 10.3 Spinal Muscular Atrophy (SMA) - Market size and forecast (2024-2029)
- Chart on Spinal Muscular Atrophy (SMA) - Market size and forecast (2024-2029) ($ million)
- Data Table on Spinal Muscular Atrophy (SMA) - Market size and forecast (2024-2029) ($ million)
- Chart on Spinal Muscular Atrophy (SMA) - Year-over-year growth (2024-2029) (%)
- Data Table on Spinal Muscular Atrophy (SMA) - Year-over-year growth (2024-2029) (%)
- 10.4 Muscular Dystrophy (e.g., Duchenne, Becker) - Market size and forecast (2024-2029)
- Chart on Muscular Dystrophy (e.g., Duchenne, Becker) - Market size and forecast (2024-2029) ($ million)
- Data Table on Muscular Dystrophy (e.g., Duchenne, Becker) - Market size and forecast (2024-2029) ($ million)
- Chart on Muscular Dystrophy (e.g., Duchenne, Becker) - Year-over-year growth (2024-2029) (%)
- Data Table on Muscular Dystrophy (e.g., Duchenne, Becker) - Year-over-year growth (2024-2029) (%)
- 10.5 Amyotrophic Lateral Sclerosis (ALS) - Market size and forecast (2024-2029)
- Chart on Amyotrophic Lateral Sclerosis (ALS) - Market size and forecast (2024-2029) ($ million)
- Data Table on Amyotrophic Lateral Sclerosis (ALS) - Market size and forecast (2024-2029) ($ million)
- Chart on Amyotrophic Lateral Sclerosis (ALS) - Year-over-year growth (2024-2029) (%)
- Data Table on Amyotrophic Lateral Sclerosis (ALS) - Year-over-year growth (2024-2029) (%)
- 10.6 Myasthenia Gravis - Market size and forecast (2024-2029)
- Chart on Myasthenia Gravis - Market size and forecast (2024-2029) ($ million)
- Data Table on Myasthenia Gravis - Market size and forecast (2024-2029) ($ million)
- Chart on Myasthenia Gravis - Year-over-year growth (2024-2029) (%)
- Data Table on Myasthenia Gravis - Year-over-year growth (2024-2029) (%)
- 10.7 Inflammatory - Market size and forecast (2024-2029)
- Chart on Inflammatory - Market size and forecast (2024-2029) ($ million)
- Data Table on Inflammatory - Market size and forecast (2024-2029) ($ million)
- Chart on Inflammatory - Year-over-year growth (2024-2029) (%)
- Data Table on Inflammatory - Year-over-year growth (2024-2029) (%)
- 10.8 Myopathies - Market size and forecast (2024-2029)
- Chart on Myopathies - Market size and forecast (2024-2029) ($ million)
- Data Table on Myopathies - Market size and forecast (2024-2029) ($ million)
- Chart on Myopathies - Year-over-year growth (2024-2029) (%)
- Data Table on Myopathies - Year-over-year growth (2024-2029) (%)
- 10.9 Others - Market size and forecast (2024-2029)
- Chart on Others - Market size and forecast (2024-2029) ($ million)
- Data Table on Others - Market size and forecast (2024-2029) ($ million)
- Chart on Others - Year-over-year growth (2024-2029) (%)
- Data Table on Others - Year-over-year growth (2024-2029) (%)
11 Market Segmentation by Therapeutic Approach
- 11.1 Market segments
- Chart on Therapeutic Approach - Market share (2024-2029) (%)
- Data Table on Therapeutic Approach - Market share (2024-2029) (%)
- 11.2 Comparison by Therapeutic Approach
- Chart on Comparison by Therapeutic Approach
- Data Table on Comparison by Therapeutic Approach
- 11.3 Gene Therapy - Market size and forecast (2024-2029)
- Chart on Gene Therapy - Market size and forecast (2024-2029) ($ million)
- Data Table on Gene Therapy - Market size and forecast (2024-2029) ($ million)
- Chart on Gene Therapy - Year-over-year growth (2024-2029) (%)
- Data Table on Gene Therapy - Year-over-year growth (2024-2029) (%)
- 11.4 Monoclonal Antibodies - Market size and forecast (2024-2029)
- Chart on Monoclonal Antibodies - Market size and forecast (2024-2029) ($ million)
- Data Table on Monoclonal Antibodies - Market size and forecast (2024-2029) ($ million)
- Chart on Monoclonal Antibodies - Year-over-year growth (2024-2029) (%)
- Data Table on Monoclonal Antibodies - Year-over-year growth (2024-2029) (%)
- 11.5 Enzyme Replacement Therapy - Market size and forecast (2024-2029)
- Chart on Enzyme Replacement Therapy - Market size and forecast (2024-2029) ($ million)
- Data Table on Enzyme Replacement Therapy - Market size and forecast (2024-2029) ($ million)
- Chart on Enzyme Replacement Therapy - Year-over-year growth (2024-2029) (%)
- Data Table on Enzyme Replacement Therapy - Year-over-year growth (2024-2029) (%)
- 11.6 Symptom Management Drugs - Market size and forecast (2024-2029)
- Chart on Symptom Management Drugs - Market size and forecast (2024-2029) ($ million)
- Data Table on Symptom Management Drugs - Market size and forecast (2024-2029) ($ million)
- Chart on Symptom Management Drugs - Year-over-year growth (2024-2029) (%)
- Data Table on Symptom Management Drugs - Year-over-year growth (2024-2029) (%)
- 11.7 Regenerative Therapies - Market size and forecast (2024-2029)
- Chart on Regenerative Therapies - Market size and forecast (2024-2029) ($ million)
- Data Table on Regenerative Therapies - Market size and forecast (2024-2029) ($ million)
- Chart on Regenerative Therapies - Year-over-year growth (2024-2029) (%)
- Data Table on Regenerative Therapies - Year-over-year growth (2024-2029) (%)
- 11.8 Market opportunity by Therapeutic Approach
- Market opportunity by Therapeutic Approach ($ million)
- Data Table on Market opportunity by Therapeutic Approach ($ million)
12 Market Segmentation by Application
- 12.1 Market segments
- Chart on Application - Market share (2024-2029) (%)
- Data Table on Application - Market share (2024-2029) (%)
- 12.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 12.3 Pediatric Patients - Market size and forecast (2024-2029)
- Chart on Pediatric Patients - Market size and forecast (2024-2029) ($ million)
- Data Table on Pediatric Patients - Market size and forecast (2024-2029) ($ million)
- Chart on Pediatric Patients - Year-over-year growth (2024-2029) (%)
- Data Table on Pediatric Patients - Year-over-year growth (2024-2029) (%)
- 12.4 Adult Patients - Market size and forecast (2024-2029)
- Chart on Adult Patients - Market size and forecast (2024-2029) ($ million)
- Data Table on Adult Patients - Market size and forecast (2024-2029) ($ million)
- Chart on Adult Patients - Year-over-year growth (2024-2029) (%)
- Data Table on Adult Patients - Year-over-year growth (2024-2029) (%)
- 12.5 Acute vs. Chronic Treatment - Market size and forecast (2024-2029)
- Chart on Acute vs. Chronic Treatment - Market size and forecast (2024-2029) ($ million)
- Data Table on Acute vs. Chronic Treatment - Market size and forecast (2024-2029) ($ million)
- Chart on Acute vs. Chronic Treatment - Year-over-year growth (2024-2029) (%)
- Data Table on Acute vs. Chronic Treatment - Year-over-year growth (2024-2029) (%)
- 12.6 Market opportunity by Application
- Market opportunity by Application ($ million)
- Data Table on Market opportunity by Application ($ million)
13 Market Segmentation by Product Tier
- 13.1 Market segments
- Chart on Product Tier - Market share (2024-2029) (%)
- Data Table on Product Tier - Market share (2024-2029) (%)
- 13.2 Comparison by Product Tier
- Chart on Comparison by Product Tier
- Data Table on Comparison by Product Tier
- 13.3 Branded Drugs - Market size and forecast (2024-2029)
- Chart on Branded Drugs - Market size and forecast (2024-2029) ($ million)
- Data Table on Branded Drugs - Market size and forecast (2024-2029) ($ million)
- Chart on Branded Drugs - Year-over-year growth (2024-2029) (%)
- Data Table on Branded Drugs - Year-over-year growth (2024-2029) (%)
- 13.4 Biosimilars/Generics - Market size and forecast (2024-2029)
- Chart on Biosimilars/Generics - Market size and forecast (2024-2029) ($ million)
- Data Table on Biosimilars/Generics - Market size and forecast (2024-2029) ($ million)
- Chart on Biosimilars/Generics - Year-over-year growth (2024-2029) (%)
- Data Table on Biosimilars/Generics - Year-over-year growth (2024-2029) (%)
- 13.5 Premium vs. Affordable Therapies - Market size and forecast (2024-2029)
- Chart on Premium vs. Affordable Therapies - Market size and forecast (2024-2029) ($ million)
- Data Table on Premium vs. Affordable Therapies - Market size and forecast (2024-2029) ($ million)
- Chart on Premium vs. Affordable Therapies - Year-over-year growth (2024-2029) (%)
- Data Table on Premium vs. Affordable Therapies - Year-over-year growth (2024-2029) (%)
- 13.6 Market opportunity by Product Tier
- Market opportunity by Product Tier ($ million)
- Data Table on Market opportunity by Product Tier ($ million)
14 Customer Landscape
- 14.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
15 Geographic Landscape
- 15.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 15.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 15.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ million)
- Data Table on North America - Market size and forecast 2024-2029 ($ million)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- 15.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ million)
- Data Table on Europe - Market size and forecast 2024-2029 ($ million)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- 15.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ million)
- Data Table on Asia - Market size and forecast 2024-2029 ($ million)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- 15.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- 15.7 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ million)
- Data Table on US - Market size and forecast 2024-2029 ($ million)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 15.8 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ million)
- Data Table on Germany - Market size and forecast 2024-2029 ($ million)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 15.9 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ million)
- Data Table on UK - Market size and forecast 2024-2029 ($ million)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 15.10 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ million)
- Data Table on China - Market size and forecast 2024-2029 ($ million)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 15.11 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ million)
- Data Table on Canada - Market size and forecast 2024-2029 ($ million)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 15.12 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ million)
- Data Table on France - Market size and forecast 2024-2029 ($ million)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 15.13 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ million)
- Data Table on Japan - Market size and forecast 2024-2029 ($ million)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 15.14 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ million)
- Data Table on India - Market size and forecast 2024-2029 ($ million)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 15.15 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ million)
- Data Table on Italy - Market size and forecast 2024-2029 ($ million)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 15.16 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ million)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ million)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 15.17 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
- 15.18 Rest of World(Row) - Market size and forecast (2024-2029)
- Chart on Rest of World(Row) - Market size and forecast (2024-2029) ($ million)
- Data Table on Rest of World(Row) - Market size and forecast (2024-2029) ($ million)
- Chart on Rest of World(Row) - Year-over-year growth (2024-2029) (%)
- Data Table on Rest of World(Row) - Year-over-year growth (2024-2029) (%)
16 Drivers, Challenges, and Opportunity/Restraints
- 16.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 16.4 Market opportunities/restraints
17 Competitive Landscape
- 17.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 17.3 Landscape disruption
- Overview on factors of disruption
- 17.4 Industry risks
- Impact of key risks on business
18 Competitive Analysis
- 18.2 Market positioning of companies
- Matrix on companies position and classification
- 18.3 AbbVie Inc. (United States)
- AbbVie Inc. (United States) - Overview
- AbbVie Inc. (United States) - Product / Service
- AbbVie Inc. (United States) - Key offerings
- 18.4 Aquestive Therapeutics Inc (United States)
- Aquestive Therapeutics Inc (United States) - Overview
- Aquestive Therapeutics Inc (United States) - Product / Service
- Aquestive Therapeutics Inc (United States) - Key offerings
- 18.5 argenx SE (Netherlands)
- argenx SE (Netherlands) - Overview
- argenx SE (Netherlands) - Product / Service
- argenx SE (Netherlands) - Key offerings
- 18.6 AstraZeneca Plc (United Kingdom)
- AstraZeneca Plc (United Kingdom) - Overview
- AstraZeneca Plc (United Kingdom) - Product / Service
- AstraZeneca Plc (United Kingdom) - Key offerings
- 18.7 Biogen Inc. (United States)
- Biogen Inc. (United States) - Overview
- Biogen Inc. (United States) - Product / Service
- Biogen Inc. (United States) - Key offerings
- 18.8 CureVac (Germany)
- CureVac (Germany) - Overview
- CureVac (Germany) - Product / Service
- CureVac (Germany) - Key offerings
- 18.9 F. Hoffmann-La Roche Ltd. (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland) - Overview
- F. Hoffmann-La Roche Ltd. (Switzerland) - Product / Service
- F. Hoffmann-La Roche Ltd. (Switzerland) - Key offerings
- 18.10 Grifols SA (Spain)
- Grifols SA (Spain) - Overview
- Grifols SA (Spain) - Product / Service
- Grifols SA (Spain) - Key offerings
- 18.11 Merck & Co. Inc. (United States)
- Merck & Co. Inc. (United States) - Overview
- Merck & Co. Inc. (United States) - Product / Service
- Merck & Co. Inc. (United States) - Key offerings
- 18.12 Nippon Shinyaku Co. Ltd. (Japan)
- Nippon Shinyaku Co. Ltd. (Japan) - Overview
- Nippon Shinyaku Co. Ltd. (Japan) - Product / Service
- Nippon Shinyaku Co. Ltd. (Japan) - Key offerings
- 18.13 Novartis AG (Switzerland)
- Novartis AG (Switzerland) - Overview
- Novartis AG (Switzerland) - Product / Service
- Novartis AG (Switzerland) - Key offerings
- 18.14 Pfizer Inc. (United States)
- Pfizer Inc. (United States) - Overview
- Pfizer Inc. (United States) - Product / Service
- Pfizer Inc. (United States) - Key offerings
- 18.15 Roivant Sciences Ltd. (United Kingdom)
- Roivant Sciences Ltd. (United Kingdom) - Overview
- Roivant Sciences Ltd. (United Kingdom) - Product / Service
- Roivant Sciences Ltd. (United Kingdom) - Key offerings
- 18.16 Santhera Pharmaceuticals Holding AG (Switzerland)
- Santhera Pharmaceuticals Holding AG (Switzerland) - Overview
- Santhera Pharmaceuticals Holding AG (Switzerland) - Product / Service
- Santhera Pharmaceuticals Holding AG (Switzerland) - Key offerings
- 18.17 Sarepta Therapeutics Inc. (United States)
- Sarepta Therapeutics Inc. (United States) - Overview
- Sarepta Therapeutics Inc. (United States) - Product / Service
- Sarepta Therapeutics Inc. (United States) - Key offerings
- 18.18 Takeda Pharmaceutical Co. Ltd. (Japan)
- Takeda Pharmaceutical Co. Ltd. (Japan) - Overview
- Takeda Pharmaceutical Co. Ltd. (Japan) - Product / Service
- Takeda Pharmaceutical Co. Ltd. (Japan) - Key offerings
- 18.19 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key offerings
- 18.20 Aquestive Therapeutics Inc
- Aquestive Therapeutics Inc - Overview
- Aquestive Therapeutics Inc - Product / Service
- Aquestive Therapeutics Inc - Key offerings
- 18.21 argenx SE
- argenx SE - Overview
- argenx SE - Product / Service
- argenx SE - Key offerings
- 18.22 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key offerings
- 18.23 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key offerings
- 18.24 CuraVac
- CuraVac - Overview
- CuraVac - Product / Service
- CuraVac - Key offerings
- 18.25 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Product / Service
- F. Hoffmann La Roche Ltd. - Key offerings
- 18.26 Grifols SA
- Grifols SA - Overview
- Grifols SA - Product / Service
- Grifols SA - Key offerings
- 18.27 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Product / Service
- Merck and Co. Inc. - Key offerings
- 18.28 Nippon Shinyaku Co. Ltd.
- Nippon Shinyaku Co. Ltd. - Overview
- Nippon Shinyaku Co. Ltd. - Product / Service
- Nippon Shinyaku Co. Ltd. - Key offerings
- 18.29 Novartis AG
- Novartis AG - Overview
- Novartis AG - Product / Service
- Novartis AG - Key offerings
- 18.30 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key offerings
- 18.31 Roivant Sciences Ltd.
- Roivant Sciences Ltd. - Overview
- Roivant Sciences Ltd. - Product / Service
- Roivant Sciences Ltd. - Key offerings
- 18.32 Santhera Pharmaceuticals Holding AG
- Santhera Pharmaceuticals Holding AG - Overview
- Santhera Pharmaceuticals Holding AG - Product / Service
- Santhera Pharmaceuticals Holding AG - Key offerings
- 18.33 Sarepta Therapeutics Inc.
- Sarepta Therapeutics Inc. - Overview
- Sarepta Therapeutics Inc. - Product / Service
- Sarepta Therapeutics Inc. - Key offerings
- 18.34 Takeda Pharmaceutical Co. Ltd.
- Takeda Pharmaceutical Co. Ltd. - Overview
- Takeda Pharmaceutical Co. Ltd. - Product / Service
- Takeda Pharmaceutical Co. Ltd. - Key offerings
19 Appendix
- 19.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 19.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 19.4 Research methodology
- 19.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 19.9 360 degree market analysis
- 360 degree market analysis
- 19.10 List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
